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Abstract GD1K ganglioside-replica peptides were recently
isolated from a phage-displayed random pentadecapeptide
library by assaying for inhibition of adhesion of RAW117-H10
lymphosarcoma cells to hepatic sinusoidal microvessel endothe-
lial (HSE) cells. We show here that the Trp-His-Trp (WHW)
peptide was identified as a minimal sequence of the GD1K-
replica peptide WHWRHRIPLQLAAGR. The addition of
WHW peptide-attached liposomes displayed efficient inhibition
of liver metastasis of RAW117-H10 cells as well as of GD1K-
mediated adhesion of RAW117-H10 cells to HSE cells in vitro.
These results suggest that engineered liposomes for peptide
delivery are applicable to treatment for metastasis.
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1. Introduction
Modern drug delivery systems should have potential advan-
tages, such as continuous maintenance of drug levels in a
therapeutically desirable range, reduction of harmful side ef-
fects due to targeted delivery to a particular cell type or tissue,
potentially decreased amount of drug needed, decreased num-
ber of dosages and possibly less invasive dosing, and facilita-
tion of drug administration for pharmaceuticals with short in
vivo half-lives [1]. Among various drug delivery systems, we
have been focusing on liposome-based delivery systems for
developing in vivo long circulation of drugs [2^7].
Metastasis is the most life-threatening event in patients with
cancer. Blood-borne cancer cells frequently form metastasis
mediated through various cell adhesion molecules. Better
understanding of the interactions between metastatic cells
and host cells in target organs would facilitate the develop-
ment of new therapeutic approaches.
In an experimental metastasis, the RAW117-H10 cell clone,
derived from parental RAW117-P cells that were originated
from murine spleen cells, are known to form approximately
200-fold more gross liver tumor nodules than did the parental
cell line [8], because of a strong correlation between high
adhesiveness of RAW117-H10 cells to hepatic sinusoidal mi-
crovessel endothelial (HSE) cells and high expression of the
ganglioside GD1K on RAW117-H10 cells [9,10].
Recently, we found that adhesion of RAW117-H10 cells to
HSE cells is inhibited by the GD1K-replica peptides that we
isolated from a phage-displayed random 15-mer peptide li-
brary [11]. In this study, we identi¢ed WHW tripeptide as a
minimal functional domain located in the GD1K-replica pep-
tide, and found that WHW tripeptide-attached liposomes e⁄-
ciently inhibited GD1K-mediated liver metastasis of RAW117-
H10 cells. Our ¢ndings suggest that appropriate liposomaliza-
tion of WHW tripeptide is applicable to therapeutic treatment
for GD1K-mediated liver metastasis.
2. Materials and methods
2.1. Cell lines, antibodies, peptides, and reagents
The low-metastatic lymphosarcoma cell line RAW117-P was estab-
lished from splenocytes of Balb/c mice by in vitro infection with
Abelson leukemia virus [12]. The RAW117-H10 cell clone is a variant
of RAW117-P cells with high metastatic potential for the liver [8,13].
RAW117-H10 and RAW117-P cells were maintained in suspension
culture in high-glucose Dulbecco’s modi¢ed Eagle’s medium
(DMEM) containing 5% heat-inactivated fetal bovine serum (FBS)
at 37‡C in a humidi¢ed CO2 incubator [5]. Hepatic sinusoidal micro-
vessel endothelial (HSE) cells were previously established from liver
cells [14], and maintained in adherent culture in Dulbecco’s modi¢ed
Eagle’s medium:Ham’s F-12 (DMEM/F12 1:1 mixture) supplemented
with 10% FBS, 10 units/ml heparin sodium, and 50 Wg/ml Endothelial
mitogen (Biomedical Technologies, Stoughton, MA, USA) in a hu-
midi¢ed CO2 incubator, as described previously [15]. RAW117-H10
cells, RAW117-P cells, and HSE cells were kindly provided by Drs.
G.L. Nicolson and T. Irimura.
The ganglioside GD1K [16^18] puri¢ed from frog livers was gener-
ously provided by Dr. M. Ohashi [18]. The monoclonal antibody
(mAb) directed against GD1K (clone KA17) was kindly provided by
Dr. Y. Hirabayashi [19]. Horseradish peroxidase (HRP)-conjugated
F(ab’)2 fragment of goat anti-mouse IgG+IgM antibody was pur-
chased from Jackson ImmunoResearch Laboratories, (West Grove,
PA, USA).
Various peptides were synthesized from Rink amide resin (0.4^
0.7 mmol/g) using a peptide synthesizer ACT357 (Advanced Chem-
Tech), resulting in the form of amide at the carboxy termini. Alkyl-
ated peptides were synthesized using the DIPCI-HOBt coupling
method and the formulas of the peptides were indicated as follows:
NH2^WHW^CO^NH^(CH2)11CO^NH2 ; NH2^WHWRHRI^CO^
NH^(CH2)7CO^NH2 ; CH3(CH2)16CO^NH^WHW^CO^NH2. The
former two were used in in vitro cell adhesion shown in Fig. 4 and
the latter one was in in vivo experimental metastasis shown in Table
1. Integration of alkylated peptides into liposomes was con¢rmed by
spectrophotometry.
2.2. Preparation of liposomes
Liposomes were prepared as described [2]. In brief, dipalmitoyl-
phosphatidyl choline (DPPC) or distearoylphosphatidylcholine
(DSPC), cholesterol, and alkylated WHW (10:5:1 or 4:2:1 as molar
ratio) dissolved in chloroform were dried under low pressure to pre-
pare thin lipid ¢lm, and stored in vacuo for at least 1 h. Liposomes
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were produced by hydration of thin lipid ¢lm with 0.3 M glucose,
freeze-thawing for three times using liquid nitrogen, and subsequent
sonication for 5 min with 50% duty cycles by using Braonson Soni¢er
(Model 250). Thus obtained liposomes were essentially small unila-
mellar vesicles. Initial concentrations of DPPC-containing liposomes
and DSPC-containing liposomes were adjusted with 0.3 M glucose to
1.3 mM as DPPC and 1.25 mM as DSPC, respectively. DPPC and
DSPC were kindly provided by Dr. Y. Namba (Nippon, Hyogo,
Japan).
2.3. Preparation of BCECF-labeled cells
Cells were labeled with 2P,7P-bis(2-carboxyethyl)-5(and 6)-carboxy-
£uorescein, acetoxymethylester (BCECF-AM, Dojindo Laboratories,
Kumamoto, Japan), as previously described [16]. In brief, RAW117
cells (1.2U106 cells/ml) were loaded with 3 WM BCECF-AM (¢nal
0.3% dimethylsulfoxide) in high-glucose DMEM containing 5%
heat-inactivated FBS for 30 min at 37‡C in a humidi¢ed CO2 incu-
bator. Cells were washed twice with phosphate-bu¡ered saline (PBS),
and suspended in high glucose DMEM containing 1% bovine serum
albumin (BSA).
2.4. Cell adhesion assay
HSE cells (6.8U105 cells/ml) were seeded in 96-microwell plates
precoated with 0.1% gelatin in PBS. Cells were cultured in DMEM/
F12 1:1 mixture containing 10% FBS, heparin, and endothelial mi-
togen overnight at 37‡C in a humidi¢ed CO2 incubator. After the
resulting monolayers were washed with PBS, 25 Wl of BCECF-labeled
cells (4U105 cells/ml) and 25 Wl of various peptides or liposomes at
the indicated concentrations were added onto HSE monolayer cells,
and incubated for 20 min at 37‡C in a humidi¢ed CO2 incubator.
Then, non-adherent cells were removed by washing with PBS. Adher-
ent cells were solubilized in 100 Wl of 10% Triton X-100 at 4‡C over-
night, and were quantitated by £uorometry. BCECF was exited at 490
nm and emission signals were detected at 526 nm.
2.5. ELISA assay
50 Wl of GD1K solution (64.34 Wg/ml methanol) was placed into
each well in 96-microwell plates (polysope, NUNC) and methanol was
evaporated. GD1K-coated plates were washed three times with Tris-
bu¡ered saline, pH 7.4 (TBS) and then blocked with TBS containing
1% BSA (200 Wl/well) for 2 h at room temperature. After washing
with TBS, 25 Wl of the anti-GD1K mAb KA17 in TBS containing
0.1% BSA and 25 Wl of various peptides or bu¡er alone were added
to each well, and incubated for 2 h at 4‡C. After washing, bound mAb
KA17 was detected by further incubation with HRP-conjugated goat
anti-mouse IgG+IgM antibody for 2 h at 4‡C. The bound antibodies
were detected by peroxidase activities using o-phenylenediamine as
substrate. The signals were measured with a microplate reader at
490 nm.
2.6. Experimental metastasis
Experimental metastasis was performed as described [5,11]. In brief,
7-week-old female Balb/c mice (SLC, Shizuoka, Japan) were anesthe-
tized with sodium pentobarbital (0.05 mg/g body weight). Mice were
cared for, according to the animal facility guidelines of the University
of Shizuoka. For injection of RAW117-H10 cells into the hepatic
portal system, an incision was made along the midline of the abdomen
to expose the mesentery. Cultured RAW117-H10 cells were washed
with high-glucose DMEM to remove FBS. Immediately after cell
suspensions (1U105 cells/0.1 ml) were mixed with either an equal
volume of liposome solution or medium alone, 0.2 ml of the mixture
was injected into mice via the portal vein. The animals (5 per group)
were killed on day 7 after injection and the livers were removed.
Establishment of metastasis was con¢rmed by pathological examina-
tion. The removed livers were weighted to determine the extent of
metastasis because of di⁄cult evaluation of RAW117 cell colonies
inside the livers.
3. Results and discussion
Our recent study showed that, of 24 independent phage
clones that we selected for inhibition of adhesion of
RAW117-H10 cells to HSE cells, 13 clones possessed the
WHW tripeptide domain in pentadecapeptides. Among
them, the phage clone displaying the WHWRHRIPLQ-
LAAGR sequence showed the highest inhibitory activity [11].
To examine the signi¢cance of the WHW sequence in ad-
hesion of RAW117-H10 cells to con£uent monolayers of HSE
cells, we synthesized mutated peptides for the ability to inhibit
the adhesion. The GD1K-replica peptide WHWRHRIPLQ-
Table 1
Suppression of experimental metastasis of RAW117-H10 cells in the liver by liposomal GD1K-replica peptide
Group Liver weight (g þ S.D.) Increase in liver weight (g þ S.D.) Inhibition (%)
Shama 0.861 þ 0.014 ^ ^
RAW117-H10 cells 1.363 þ 0.195 0.502 þ 0.195 0
RAW117-H10 cells+control liposomes 1.305 þ 0.110 0.444 þ 0.110 11.6
RAW117- H10 cells+WHW-liposomes 1.137 þ 0.040* 0.276 þ 0.040* 45.0
RAW117-H10 cells (1U105 cells/0.2 ml/mouse) were injected into mice (7-week-old Balb/c female mice, n = 5) via the portal vein with or with-
out liposomes (1.25 mM as a peptide). After 7 days, liver weight was measured for evaluating experimental metastasis of RAW117-H10 cells in
the liver. Components of liposomes were DSPC:cholesterol = 2:1 for control liposomes and DSPC:cholesterol:peptide = 4:2:1 for WHW pep-
tide-modi¢ed liposomes.
a0.2 ml of medium alone was injected into mice as a control.
*Signi¢cantly di¡erent from the liver weight of mice injected with RAW117-H10 cells alone (P6 0.05), calculated by Student’s t-test.
Fig. 1. E¡ect of the GD1K-replica peptide on adhesion of RAW117
cells to HSE cells. BCECF-labeled RAW117-H10 (A) or RAW117-P
cells (B) were added onto hepatic sinusoidal microvessel endothelial
cells (HSE) in the presence or absence of peptides (660 WM), and in-
cubated for 20 min at 37‡C. After non-adherent cells were washed
out, adherent cells were quantitated by £uorometry. Peptides used
in this study were WHWRHRIPLQLAAGR and AAARHRIPLQ-
LAAAGR. The data represent the mean þ S.D. (n = 4). An asterisk
indicates the signi¢cant di¡erence (*P6 0.01) calculated by Stu-
dent’s t-test.
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LAAGR and its alanine-substituted peptide AAARHRIPLQ-
LAAGR were compared for inhibitory e¡ects on cell adhe-
sion. Fig. 1A shows that addition of WHWRHRIPLQ-
LAAGR inhibited adhesion of RAW117-H10 cells to HSE
cells, consistent with our recent observations [11]. In contrast,
the addition of AAARHRIPLQLAAGR revealed no e¡ect on
adhesion of RAW117-H10 cells to HSE cells. Although the
extent of adhesion of parental RAW117-P cells to HSE cells
was less than 30%, no inhibition of the adhesion was observed
by the addition of WHWRHRIPLQLAAGR or AAARH-
RIPLQLAAGR (Fig. 1B). These results suggest that GD1K-
mediated adhesion of RAW117-H10 cells to HSE cells is spe-
ci¢cally blocked by WHWRHRIPLQLAAGR, and that the
WHW domain plays a critical role in the cell adhesion.
To dissect the role of the WHW domain in GD1K-mediated
cell adhesion, we created various deletion mutants of
WHWRHRIPLQLAAGR. As shown in Fig. 2, WHW pep-
tide per se as a minimal sequence exerted strong inhibitory
activity toward adhesion of RAW117-H10 cells to HSE cells.
To substantiate the binding of the WHW domain to mAb
KA17 directed against GD1K, we performed a competitive
binding assay by measuring the binding of mAb KA17 to
GD1K-coated plates in the presence of various peptides. Fig.
3 shows that WHW peptide as well as WHW-containing pep-
tides inhibited the binding of mAb KA17 to GD1K, suggest-
ing that the WHW domain is a minimal sequence mimicking
the GD1K epitope recognized by mAb KA17.
Liposomes coated with high densities of peptides are useful
for drug delivery to target organs that express receptors for
the peptides. We therefore tested whether WHW-containing
peptides covalently attached to liposomes could e⁄ciently in-
hibit adhesion of RAW117-H10 cells to HSE cells that express
hypothetical GD1K receptors. As shown in Fig. 4, the speci¢c
activity of WHW-containing peptides for inhibition increased
approximately two-fold in case of liposomalization of the pep-
tides (compare with the results using soluble peptides in Fig.
2). The inhibitory activity of liposomes modi¢ed with trimer
peptides was stronger than those modi¢ed with 7-mer pep-
tides, since the trimer peptide derivative was incorporated in
a lipid bilayer more stable due to the hydrophilic-lipophilic
balance than the 7-mer one. Thus the following experiment
was performed by using palmitoyl-WHW, which was stably
incorporated into the lipid bilayer of liposomes.
To ascertain whether WHW-attached liposomes were e¡ec-
tive for the inhibition of adhesion of RAW117-H10 cells to
HSE cells in vivo, we performed experimental metastasis of
RAW117-H10 cells in the liver. Injection of RAW117-H10
cells into mice via the portal vein brought about increases in
liver weight (approximately 158%) after 7 days (Table 1).
Metastasis of RAW117-H10 cells to the liver was con¢rmed
by pathological examination and the extent of the metastasis
Fig. 2. Identi¢cation of a minimal sequence of the GD1K-replica
peptide for inhibition of cell adhesion. Adhesion of RAW117-H10
cells to HSE cells was analyzed to the presence or absence of the in-
dicated concentrations of peptides (WM) (A), as described in Fig. 1.
Various peptides were used at a concentration of 660 WM (B). The
data represent the mean þ S.D. (n = 4). Asterisks indicate signi¢cant
di¡erences (A, *P6 0.05, **P6 0.01; B, *P6 0.01) calculated by
Student’s t test.
Fig. 3. E¡ect of WHW peptides on the binding of anti-GD1K mAb
to GD1K. Anti-GD1K mAb was added to ELISA plates coated
with GD1K in the presence or absence of various peptides (1.32
mM), and incubated for 2 h at 4‡C. The binding of anti-GD1K
mAb to GD1K was measured by ELISA using HRP-conjugated sec-
ondary Ab, and expressed as the values (means (%) (n = 2)) relative
to the reactivity in the absence of peptides.
Fig. 4. E¡ect of GD1K-replica peptide-attached liposomes on adhe-
sion of RAW117-H10 cells to HSE cells. Adhesion of RAW117-
H10 cells to HSE cells was analyzed in the presence or absence of
peptide-attached liposomes, as described in Fig. 1. Peptide-attached
liposomes (DPPC:cholesterol:peptide = 10:5:1) were used at the in-
dicated concentrations of peptides present in liposomes (WM). Con-
trol liposomes (DPPC:cholesterol = 2:1) were prepared without pep-
tides. Concentrations of liposomes expressed as DPPC
concentrations (WM) were given in parentheses. The data represent
the mean þ S.D. (n = 4). Asterisks indicate signi¢cant di¡erence
(*P6 0.001) calculated by Student’s t-test.
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was evaluated by an increase in liver weight. Intriguingly, the
experimental liver metastasis was drastically inhibited by the
addition of WHW peptide-attached liposomes. In contrast,
the addition of soluble WHW peptide did not a¡ect the ex-
perimental liver metastasis, presumably because of short in
vivo half-life of this tripeptide (data not shown). These results
suggest that WHW peptide-attached liposomes competitively
block the binding of GD1K expressed on RAW117-H10 cells
to hypothetical GD1K receptors present on hepatic sinusoidal
endothelial cells. This event could lead to the inhibition of
extravasation of RAW117-H10 cells from liver blood vessels.
Attachment of peptides to the surface of liposomes can
enhance their stability in vivo and confer high availability
for binding to their receptors, because proper orientation
and well-controlled density of peptides on the liposome sur-
face are easily achieved. In the present study, we identi¢ed
WHW peptide as a minimal sequence of the GD1K-replica
peptide and showed that the addition of WHW peptide-at-
tached liposomes suppressed GD1K-mediated experimental
metastasis of RAW117-H10 cells in the liver. Given that the
size of WHW peptide is small, we imagine that GD1K recep-
tors can recognize WHW peptide as a haptenic molecule.
Use of phage-displayed random peptide libraries enables us
to search for new peptide sequences targeting selective organs,
tissues and cells in vivo [20,21]. Identi¢cation of minimal pep-
tide sequences that actually function can prevent side e¡ects
which might stem from full-length peptides. Liposome-based
drug delivery systems utilizing ligand-mimicking haptenic pep-
tides will be useful for e⁄cient inhibition of ligand-receptor
interactions in cell adhesion such as tumor metastasis.
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